NFKB1 and pulmonary arterial hypertension: NF-κB expression increases during SCLCs as compared to NSCLCs [31] and in lung damage induced by hyperoxia [68], oxidative stress [69] and in number of pulmonary disease including cystic fibrosis, pulmonary hypertension and cancer [70].